98%
921
2 minutes
20
The full length genes gyrB (2,415 bp), parC (2,277 bp), and parE (1,896 bp) in Edwardsiella tarda were cloned by PCR with degenerate primers based on the sequence of the respective quinolone resistance-determining region (QRDR), followed by elongation of 5' and 3' ends using cassette ligation-mediated PCR (CLMP). Analysis of the cloned genes revealed open reading frames (ORFs) encoding proteins of 804 (GyrB), 758 (ParC), and 631 (ParE) amino acids with conserved gyrase/topoisomerase features and motifs important for enzymatic function. The ORFs were preceded by putative promoters, ribosome binding sites, and inverted repeats with the potential to form cruciform structures for binding of DNA-binding proteins. When comparing the deduced amino acid sequences of E. tarda GyrB, ParC, and ParE with those of the corresponding proteins in other bacteria, they were found to be most closely related to Escherichia coli GyrB (87.6% identity), Klebsiella pneumoniae ParC (78.8% identity) and Salmonella typhimurium ParE (89.5% identity), respectively. The two topoisomerase genes, parC and parE, were found to be contiguous on the E. tarda chromosome. All 18 quinoloneresistant isolates obtained from Korea thus far did not contain subunit alternations apart from a substitution in GyrA (Ser83→Arg). However, an alteration in the QRDR of ParC (Ser84→Ile) following an amino acid substitution in GyrA (Asp87→Gly) was detected in E. tarda mutants selected in vitro at 8 microng/ml ciprofloxacin (CIP). A mutant with a GyrB (Ser464→Leu) and GyrA (Asp87→Gly) substitution did not show a significant increase in the minimum inhibitory concentration (MIC) of CIP. None of the in vitro mutants exhibited mutations in parE. Thus, gyrA and parC should be considered to be the primary and secondary targets, respectively, of quinolones in E. tarda.
Download full-text PDF |
Source |
---|
Pathogens
August 2025
Department of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 2-6-2 Otani-cho, Nagata-ku, Kobe 653-0838, Japan.
The DNA synthesis inhibitor zoliflodacin (ZFD) is expected to be effective against strains resistant to therapeutic agents for infection. In addition to ZFD, we investigated the susceptibility of strains to ceftriaxone (CTRX), ciprofloxacin (CPFX), garenoxacin (GRNX), and sitafloxacin (STFX). Minimum inhibitory concentration values for ZFD and four other drugs were determined for 147 strains of isolated at medical institutions in Hyogo Prefecture, Japan, from 2015 to 2022.
View Article and Find Full Text PDFArch Phys Med Rehabil
August 2025
Service de Médecine Physique et de Réadaptation, Hôpital Lariboisière-Fernand Widal, Université Paris Cité, AP-HP, 2, rue Ambroise-Paré, Paris, France.
Objective: To investigate the economic impact of work disability due to chronic low back pain (cLBP) from the patient's perspective.
Design: We conducted a retrospective monocentric cross-sectional study from January 2010 to December 2019.
Setting: The study was conducted in a university hospital in a tertiary care setting.
J Antimicrob Chemother
August 2025
Unidad de Microbiología Clínica, Laboratorio Regional de Salud Pública de la Comunidad de Madrid, Madrid, Spain.
Background: Delafloxacin is a dual-targeting fluoroquinolone against topoisomerase IV and DNA gyrase that could decrease resistance selection by diminishing the likelihood of multiple mutational events in both enzymes.
Objectives: To determine the activity of delafloxacin against invasive Streptococcus pneumoniae isolates resistant to levofloxacin (LEV-R), compare delafloxacin MICs for LEV-R isolates with those of susceptible strains, and analyse mutations in QRDRs.
Methods: A total of 130 S.
Pak J Pharm Sci
August 2025
Provincial Public Health Laboratory Balochistan, Pakistan.
Extensive drug resistance (XDR) S. typhi have been evaluated in patients with gastrointestinal disturbance who attended multiple tertiary care hospitals in Quetta, Balochistan, Pakistan. Blood samples of total of 480 patients were obtained and S.
View Article and Find Full Text PDFInfect Drug Resist
July 2025
Department of Laboratory Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430016, People's Republic of China.
Objective: This study aims to delineate the epidemiological characteristics and antibiotic resistance of isolates from Wuhan, focusing on serotype distribution, resistance patterns, and genetic diversity.
Methods: Our study analyzed 40 isolates collected from 2011 to 2022 in Wuhan, assessing their serotype distribution and resistance to multiple antibiotics. We conducted resistance gene detection and genetic diversity analysis using polymerase chain reaction and pulsed-field gel electrophoresis (PFGE), respectively.